Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Purpose of kinsenoside to preparation of medicines for preventing and treating neurogenic inflammation

A technique of clematis and neuroinflammation, applied in the field of use of clematis in the preparation of medicines for preventing and treating neuroinflammation

Active Publication Date: 2019-12-20
福建金兰厚普生物科技有限公司
View PDF7 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0006] Clematis glucoside is a chemical component extracted from Clematis clematis of Orchidaceae. Pharmacological studies have shown that it has the effects of lowering blood sugar, lowering blood fat, protecting liver and improving osteoporosis, etc., but it has not yet been found. Reports of any effect on neuroinflammation

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Purpose of kinsenoside to preparation of medicines for preventing and treating neurogenic inflammation
  • Purpose of kinsenoside to preparation of medicines for preventing and treating neurogenic inflammation
  • Purpose of kinsenoside to preparation of medicines for preventing and treating neurogenic inflammation

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0038]Example 1 Experiment of auroside inhibiting the expression of inflammatory factor TNFα

[0039] The experimental steps are as follows: ① Seed BV2 microglial cells in a 12-well cell culture plate, 100,000 cells / well; ② After 12 hours, pretreat with auroside with a final concentration of 20 μM (the molar concentration of the stock solution is 80 mM) 1h, the cells that were not pretreated with auroglutinin were used as the unstimulated control group; ③The cells pretreated with auroglutinin for 1h were divided into two groups, and lipopolysaccharide (LPS) was added (final concentration: 1 μg / ml). One group was stimulated with LPS for 12 hours, and the other group was stimulated with LPS for 24 hours; ④ When LPS was stimulated to the predetermined time point, the cells were lysed with Trizol reagent, and RNA was extracted; ⑤ After RNA was extracted, 1 μg of total RNA was taken from each sample, and random The primers were reverse-transcribed to obtain cDNA. The cDNA was quan...

Embodiment 2

[0044] Example 2 Experiment of auroside inhibiting the expression of inflammatory factor IL6

[0045] The experimental steps are as follows: ① Seed BV2 microglial cells in a 12-well cell culture plate, 100,000 cells / well; ② After 12 hours, pretreat with auroside with a final concentration of 20 μM (the molar concentration of the stock solution is 80 mM) 1h, the cells that were not pretreated with auroglutin were used as the unstimulated control group; ③The cells that were pretreated with auroglutin for 1h were divided into two groups, and LPS was added respectively (final concentration: 1 μg / ml), and one group LPS was stimulated for 12 hours, and the other group was stimulated with LPS for 24 hours; ④When LPS was stimulated to the predetermined time point, the cells were lysed with Trizol reagent, and RNA was extracted; Reverse transcription to obtain cDNA. The cDNA was quantified by real-time fluorescent quantitative PCR and sybergreen dye method to detect the expression o...

Embodiment 3

[0050] Example 3-Auroside inhibits the expression of the inflammatory factor iNOS

[0051] The experimental steps are as follows: ① seed BV2 microglial cells in a 12-well cell culture plate, 100,000 cells / well; ② 12 hours later, use auroside with a final concentration of 20 μM (dilute with a stock solution with a molar concentration of 80 mM) The cells were pretreated for 1 hour, and the cells that were not pretreated with auroglutin were used as the unstimulated control group; ③ The cells that were pretreated for 1 hour were divided into two groups, and LPS (final concentration: 1 μg / ml) was added respectively. One group was stimulated with LPS for 12 hours, and the other group was stimulated with LPS for 24 hours; ④ When LPS was stimulated to the predetermined time point, the cells were lysed with Trizol reagent and RNA was extracted; Random primers were used for reverse transcription to obtain cDNA. The cDNA was carried out by real-time fluorescence quantitative PCR, and...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses a purpose of kinsenoside or pharmaceutically-acceptable salt thereof to preparation of medicines for preventing and treating neurogenic inflammation. The kinsenoside or the pharmaceutically-acceptable salt thereof can effectively prevent and treat the neurogenic inflammation, and can treat nervous system diseases caused by the neurogenic inflammation.

Description

technical field [0001] The present invention relates to the pharmaceutical use of the compound, in particular to the use of auroside or a pharmaceutically acceptable salt thereof in the preparation of medicines for preventing and treating neuroinflammation. Background technique [0002] Neuroinflammation is mainly a process in which glial cells of the central nervous system are stimulated by foreign pathogens or some components of themselves, resulting in increased expression of inflammatory genes and release to the peripheral nerve microenvironment. Changes in the neural microenvironment due to the release of inflammatory factors are not conducive to neuron survival and synapse pruning, thereby promoting the occurrence of certain neurological diseases. [0003] The main immune cells in the nervous system are microglia, and neuroinflammation is mainly mediated by these cells. Microglia and peripheral macrophages have some similar characteristics during activation, for examp...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61K36/898A61P25/00A61P29/00A61P25/28A61P25/16A61P9/10
CPCA61K31/7048A61K36/898A61P9/10A61P25/00A61P25/16A61P25/28A61P29/00
Inventor 袁增强潘瑞远廖亚金张海燕
Owner 福建金兰厚普生物科技有限公司
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com